Steve Oconnor
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2019First federal award
$1.2MFederal grants as PI5 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
5 awards · $1.2M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 17, 2026 | NIH | STTR Phase I Anti-sense oligonucleotide inhibitors of retinoic acid signaling and reversion of retinal remodeling for mitigating vision loss | $37K | Shift Pharmaceuticals Holdings, Inc. |
| Aug 1, 2025 | NIH | STTR Phase I Anti-sense oligonucleotide inhibitors of retinoic acid signaling and reversion of retinal remodeling for mitigating vision loss | $312K | Shift Pharmaceuticals Holdings, Inc. |
| Apr 1, 2023 | NIH | SBIR Phase I IND Enabling Non-Clinical Development of E1v1.11, a Morpholino Anti-Sense Oligonucleotide for the treatment of Spinal Muscular Atrophy. | $361K | Shift Pharmaceuticals Holdings, Inc. |
| Jun 1, 2022 | NIH | SBIR Phase I Development of novel ASO-based therapeutics for CMT1A | $257K | Shift Pharmaceuticals Holdings, Inc. |
| Sep 15, 2019 | NIH | SBIR Phase I Multi-dose pre-clinical studies in rat for E1-targeting antisense oligonucleotides | $228K | Shift Pharmaceuticals Holdings, Inc. |
Peer ranks
Federal funding#1,604
Awards as PI#417
Patents#273
Companies
- Shift Pharmaceuticals Holdings, Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.